Monopar Therapeutics Inc.
NASDAQ:MNPRBiotechnology
+$1.58 today
- Market cap
- $479.46M
- Beta
- 1.54
- P/E (TTM)
- -37.6
- EPS (TTM)
- -$1.76
Volume 0.10M
Average 0.17M
Balance Sheet
Inspect the capital base behind the business.
Assets
$140.72M
FY 2025 · Annual
+133.4% YoYLiabilities
$2.89M
FY 2025 · Annual
-45.0% YoYEquity
$137.83M
FY 2025 · Annual
+150.4% YoYBalance Sheet
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $52.5M |
| Short-term Investments | $84.9M |
| Other Current | $250.9K |
| Total Current Assets | $137.7M |
| PP&E (Net) | $239.9K |
| Total Non-current Assets | $239.9K |
| Total Assets | $138.0M |
Analysis
Selected assets total $138.0M for Latest. The largest visible component is Short-term Investments at $84.9M, about 61.6% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 12, 2026 | |
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 4, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 4, 2026 | |
| SC 13G | SC 13G filing | Oct 27, 2026 |
How much cash does MNPR have?
Monopar Therapeutics Inc. (MNPR) reported $61.83M in cash and equivalents in fiscal 2025.
How much debt does MNPR carry?
Monopar Therapeutics Inc. (MNPR) reported $154,920.00 of total debt, with net debt of -$61.68M.
Continue the stock analysis
Jump to another research area for this company.